Takefumi Ishii

1.2k total citations
20 papers, 962 citations indexed

About

Takefumi Ishii is a scholar working on Genetics, Hematology and Rheumatology. According to data from OpenAlex, Takefumi Ishii has authored 20 papers receiving a total of 962 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Genetics, 12 papers in Hematology and 8 papers in Rheumatology. Recurrent topics in Takefumi Ishii's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (11 papers), Eosinophilic Disorders and Syndromes (8 papers) and Chronic Myeloid Leukemia Treatments (8 papers). Takefumi Ishii is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (11 papers), Eosinophilic Disorders and Syndromes (8 papers) and Chronic Myeloid Leukemia Treatments (8 papers). Takefumi Ishii collaborates with scholars based in United States, Japan and Türkiye. Takefumi Ishii's co-authors include Mingjiang Xu, Ronald Hoffman, E Bruno, Kohichiro Tsuji, Yasuhiro Ebihara, Tatsutoshi Nakahata, Yan Zhao, Shigetaka Asano, Wen‐Yang Hu and Ryuhei Tanaka and has published in prestigious journals such as Journal of Biological Chemistry, Blood and The Journal of Immunology.

In The Last Decade

Takefumi Ishii

20 papers receiving 943 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Takefumi Ishii United States 15 556 523 390 217 211 20 962
Jennifer Adelsperger United States 5 444 0.8× 155 0.3× 417 1.1× 89 0.4× 222 1.1× 6 793
Sandra Moore United States 9 1.1k 2.0× 1.3k 2.5× 978 2.5× 445 2.1× 139 0.7× 11 1.7k
Antony C. Cambareri Australia 12 505 0.9× 342 0.7× 204 0.5× 233 1.1× 229 1.1× 14 885
Gabriele Gugliotta Italy 20 857 1.5× 704 1.3× 246 0.6× 377 1.7× 83 0.4× 60 1.1k
Irina Sadovnik Austria 18 551 1.0× 273 0.5× 452 1.2× 152 0.7× 262 1.2× 38 1.2k
Amy J. Zigler United States 7 415 0.7× 233 0.4× 278 0.7× 211 1.0× 165 0.8× 8 1.0k
Hui Hao-Shen Switzerland 17 1.2k 2.2× 1.3k 2.6× 974 2.5× 464 2.1× 161 0.8× 34 1.8k
Claudiu Cotta United States 16 182 0.3× 123 0.2× 294 0.8× 43 0.2× 126 0.6× 50 638
Mitsushige Nakao Japan 11 1.1k 2.0× 472 0.9× 602 1.5× 24 0.1× 150 0.7× 23 1.5k
Juliana Schwaab Germany 19 184 0.3× 293 0.6× 149 0.4× 553 2.5× 710 3.4× 51 994

Countries citing papers authored by Takefumi Ishii

Since Specialization
Citations

This map shows the geographic impact of Takefumi Ishii's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Takefumi Ishii with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Takefumi Ishii more than expected).

Fields of papers citing papers by Takefumi Ishii

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Takefumi Ishii. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Takefumi Ishii. The network helps show where Takefumi Ishii may publish in the future.

Co-authorship network of co-authors of Takefumi Ishii

This figure shows the co-authorship network connecting the top 25 collaborators of Takefumi Ishii. A scholar is included among the top collaborators of Takefumi Ishii based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Takefumi Ishii. Takefumi Ishii is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Wang, Xiaoli, Wei Zhang, Takefumi Ishii, et al.. (2009). Correction of the Abnormal Trafficking of Primary Myelofibrosis CD34+ Cells by Treatment with Chromatin-Modifying Agents. Cancer Research. 69(19). 7612–7618. 30 indexed citations
3.
Ishii, Takefumi, Jiapeng Wang, Wei Zhang, et al.. (2009). Pivotal role of mast cells in pruritogenesis in patients with myeloproliferative disorders. Blood. 113(23). 5942–5950. 67 indexed citations
4.
Sözer, Selçuk, Takefumi Ishii, Maria Isabel Fiel, et al.. (2009). Human CD34+ cells are capable of generating normal and JAK2V617F positive endothelial like cells in vivo. Blood Cells Molecules and Diseases. 43(3). 304–312. 26 indexed citations
5.
Wang, Xiaoli, Wei Zhang, Takefumi Ishii, et al.. (2008). Correction of the Abnormal Trafficking of Primary Myelofibrosis CD34+ Cells by Treatment with Chromatin Modifying Agents. Blood. 112(11). 101–101. 3 indexed citations
6.
Taketani, Takeshi, Tomohiko Taki, Masahiro Sako, et al.. (2008). MNX1–ETV6 fusion gene in an acute megakaryoblastic leukemia and expression of the MNX1 gene in leukemia and normal B cell lines. Cancer Genetics and Cytogenetics. 186(2). 115–119. 20 indexed citations
7.
Ishii, Takefumi, Jiapeng Wang, Wei Zhang, et al.. (2008). Mast Cells Are Involved by the Malignant Process and Play An Important Role in the Pruritogenesis in Patients with Myeloproliferative Disorders. Blood. 112(11). 3729–3729. 1 indexed citations
8.
Sözer, Selçuk, Xiaoli Wang, Wei Zhang, et al.. (2008). Circulating angiogenic monocyte progenitor cells are reduced in JAK2V617F high allele burden myeloproliferative disorders. Blood Cells Molecules and Diseases. 41(3). 284–291. 11 indexed citations
9.
Ishii, Takefumi, Yan Zhao, Selçuk Sözer, et al.. (2007). Behavior of CD34+ cells isolated from patients with polycythemia vera in NOD/SCID mice. Experimental Hematology. 35(11). 1633–1640. 33 indexed citations
10.
Shi, Jun, Yan Zhao, Takefumi Ishii, et al.. (2007). Effects of Chromatin-Modifying Agents on CD34+ Cells from Patients with Idiopathic Myelofibrosis. Cancer Research. 67(13). 6417–6424. 49 indexed citations
11.
Ciurea, Stefan O., Nadim Mahmud, Takefumi Ishii, et al.. (2007). Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood. 110(3). 986–993. 159 indexed citations
12.
Li, Zhe, Mingjiang Xu, Shu Xing, et al.. (2006). Erlotinib Effectively Inhibits JAK2V617F Activity and Polycythemia Vera Cell Growth. Journal of Biological Chemistry. 282(6). 3428–3432. 100 indexed citations
13.
14.
Ishii, Takefumi, E Bruno, Ronald Hoffman, & Mingjiang Xu. (2006). Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera. Blood. 108(9). 3128–3134. 106 indexed citations
15.
Matsuoka, Sahoko, Kohichiro Tsuji, Hiroaki Hisakawa, et al.. (2001). Generation of definitive hematopoietic stem cells from murine early yolk sac and paraaortic splanchnopleures by aorta-gonad-mesonephros region–derived stromal cells. Blood. 98(1). 6–12. 134 indexed citations
16.
Ma, Feng, Mika Wada, Hiroshi Yoshino, et al.. (2001). Development of human lymphohematopoietic stem and progenitor cells defined by expression of CD34 and CD81. Blood. 97(12). 3755–3762. 18 indexed citations
17.
Matsuoka, Sahoko, Yasuhiro Ebihara, Ming-jiang Xu, et al.. (2001). CD34 expression on long-term repopulating hematopoietic stem cells changes during developmental stages. Blood. 97(2). 419–425. 100 indexed citations
18.
Maekawa, Taira & Takefumi Ishii. (2000). Chemokine/Receptor Dynamics in the Regulation of Hematopoiesis.. Internal Medicine. 39(2). 90–100. 15 indexed citations
19.
20.
Wada, Yuka, Yasuhiro Ebihara, Takefumi Ishii, et al.. (1998). A combination of stem cell factor and granulocyte colony-stimulating factor enhances the growth of human progenitor B cells supported by murine stromal cell line MS-5. European Journal of Immunology. 28(3). 855–864. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jennifer Adelsperger Breakdown of academic impact, for papers by Sandra Moore Breakdown of academic impact, for papers by Antony C. Cambareri Breakdown of academic impact, for papers by Gabriele Gugliotta Breakdown of academic impact, for papers by Irina Sadovnik Breakdown of academic impact, for papers by Amy J. Zigler Breakdown of academic impact, for papers by Hui Hao-Shen Breakdown of academic impact, for papers by Claudiu Cotta Breakdown of academic impact, for papers by Mitsushige Nakao Breakdown of academic impact, for papers by Juliana Schwaab
Rankless by CCL
2026